CDP 571

Drug Profile

CDP 571

Alternative Names: BAY 103356; BAY W 3356; CDP571; Humicade

Latest Information Update: 10 Sep 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celltech Group
  • Developer Celltech Group; PDL BioPharma
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Crohn's disease; Rheumatoid arthritis; Septic shock; Type 2 diabetes mellitus

Most Recent Events

  • 19 Aug 2003 Discontinued - Phase-II for Crohn's disease in Canada (IV)
  • 19 Aug 2003 Discontinued - Phase-II for Crohn's disease in United Kingdom (IV)
  • 19 Aug 2003 Discontinued - Phase-III for Crohn's disease in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top